About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Thailand to Copy More Patented Cancer Drugs

by Gandhi on September 25, 2007 at 6:20 PM
Font : A-A+

Thailand to Copy More Patented  Cancer Drugs

Thailand may break more patents of Western drugmakers by adding copycat versions of four cancer medicines into the nation's generic drug programs, a health official said Monday.

The National Health Security Office said it would propose the health ministry issue so-called compulsory licenses on the drugs, unless the government reaches a deal with global pharmaceutical firms to lower prices.

Advertisement

The drugs currently cost Thai patients as much as 100,000 baht (2,920 dollars) per month per person, said Sanguan Nitayarumphong, head of the office that runs a free treatment programme for the poor.

The drugs being targeted include Novartis' Imanitib.

"We might have to impose compulsory licenses of these drugs if negotiations with the patent holders fail," said Sanguan, adding talks have yet to begin.
Advertisement

"The drugs are so expensive for Thai patients. The generic version would provide them greater chance to access the drugs at much cheaper prices."

The drugs that could be affected include Imanitib and Letrozole from Novartis; Docetaxel from Sanofi-Aventis; and Erlotinib from Genentech, he said.

Sanguan said the drugs were essential for Thailand because cancer is a leading cause of death in the kingdom.

Thailand has locked horns with Western pharmaceutical giants by issuing compulsory licenses, which temporarily suspend patent protections, for expensive medications.

The government has so far approved compulsory licenses for Plavix and two key AIDS drugs -- Kaletra and Efavirenz -- and has threatened to expand its generic programs to include cancer drugs.

It has already begun importing cheaper versions from India, a major source of generic drugs.

Plavix, which can help reduce the risks of heart attack or stroke, is sold by French-based Sanofi-Aventis and its US partner, Bristol Myers-Squibb.

Source: AFP
GAN/C
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Iodine Deficiency Disorder Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 
Recommended Reading
Common Lifestyle Habits that Cause Diseases
Cigarette smoking, unhealthy diets, overuse of alcohol, and physical inactivity are some of the most...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Health Benefits of Dandelion Plant
What is dandelion? Dandelion greens are nutrition powerhouses with a wide range of health benefits. ...
Immune Checkpoint Inhibitors for Cancer Treatment
Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has appro...
Iodine Deficiency Disorder
To control IDD, the ‘National Goiter Control Program (NGCP)’ was launched which was later renamed as...
Non-Communicable Diseases
Non-Communicable Diseases (NCDs) are a group of chronic non-infectious diseases which include Cardio...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use